Neuroprotective effect of riluzole in MPTP-treated mice

Brain Res. 2001 Nov 9;918(1-2):176-81. doi: 10.1016/s0006-8993(01)02944-4.

Abstract

The neuroprotective effects of riluzole, a Na(+) channel blocker with antiglutamatergic activity, and MK-801, a blocker of N-methyl-D-aspartate (NMDA) receptors, were compared in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced depletion of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in mice. The mice were injected intraperitoneally (i.p.) with four administrations of MPTP (10 mg/kg) at 1 h intervals and then the brains were analyzed 1, 3 and 7 days after the treatment. Dopamine and DOPAC levels were significantly decreased in the striatum from 1 day after MPTP treatment. A severe depletion in dopamine and DOPAC levels was found in the striatum 3 and 7 days after MPTP treatment. Riluzole antagonized the MPTP-induced decrease in dopamine, DOPAC and HVA levels in the striatum. On the other hand, MK-801 prevented the MPTP-induced decrease in DOPAC levels, but not in dopamine levels in the striatum. An immunohistochemical study indicated that riluzole can protect against MPTP-induced neuronal damage in the substantia nigra. These results suggest that riluzole is effective against MPTP-induced neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / antagonists & inhibitors*
  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Animals
  • Dizocilpine Maleate / pharmacology
  • Dopamine / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Interactions / physiology
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Glutamic Acid / metabolism
  • Homovanillic Acid / metabolism
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neostriatum / drug effects*
  • Neostriatum / metabolism
  • Neostriatum / physiopathology
  • Neurons / drug effects
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology*
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / metabolism
  • Parkinsonian Disorders / physiopathology
  • Riluzole / pharmacology*
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Substantia Nigra / physiopathology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • 3,4-Dihydroxyphenylacetic Acid
  • Glutamic Acid
  • Dizocilpine Maleate
  • Riluzole
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine
  • Homovanillic Acid